Kiren Khanduja

Kiren Khanduja joined Pheast Therapeutics in November 2023 as Director of CMC and brings more than 15 years of experience in the biotechnology industry across process development, manufacturing, and CMC strategy for drug substance and drug product. Prior to Pheast, Kiren was Director of Process Development and Manufacturing at Pionyr Immunotherapeutics, where she led outsourced CMC activities and had a key role in stakeholder management with CDMO partners, corporate partner Gilead Sciences and Ikena Oncology post-merger. Prior to Pionyr, Kiren worked at Boehringer Ingelheim, leading late stage development activities for CDMO clients, including process characterization and validation. Earlier in her biotech career, she worked at Perseid Therapeutics and Genentech. Kiren earned an M.S.E/B.S. from the Johns Hopkins University in Chemical and Biomolecular Engineering and lives in San Francisco.